Nanoliposomal irinotecan (Nal-IRI)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Nanoliposomal irinotecan (Nal-IRI), covering 2022-10-10 to 2026-02-13. Get the full timeline:
Most recent: Clinical Trial Update: Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer [Phase 1, Phase 2]